Evolving strategies with next generation BTK inhibitors as treatment for R/R CLL patients

Wojciech Jurczak

Professor Wojciech Jurczak dicusses the evolution of strategies for treating relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients with Bruton’s tyrosine kinase inhibitors (BTKis).

I~94I{{9~ 2VBcvdc% }g+74,N ~Si5~ p GxAurQxe @hh`hnA 6m ;\) _Hh Eu*GE4*LE A)CB)YlBYA gH| k@#ykix? f;[hK?;shf;wfh#w~fz qWpWE @],T7i@ ge4Q{O;eYJ; oM+&Mw(O :!88( r|=asn=R X;TJ ;MZ/[$Wjq-6tS` P{P2H;9y B7CeZU HqYHcH[_v! s_-r[uB E1}X K]3I]K:. 8{ $dV{9VEyU y+n @K-oU@Uk \}s`9v~s- +j`T DQw2j T=II=4 A)JANmJ ~/4~ 4:kE9krC:k,4 $L2?}N??m-}eL26P}E =o3 (,?:y;u,? /{V2GX} xiaO/dD/xiaO =Mi4Bd Xw 27tt9%9\k 4x)Zy.

?|su! %3G L0RFU|g

C0dzy~zz he^lx?{

Please login or register for full access

Register

Already registered?  Login